Your browser doesn't support javascript.
loading
Assessment of the Pharmacokinetics and Safety of Spesolimab, a Humanised Anti-interleukin-36 Receptor Monoclonal Antibody, in Healthy Non-Japanese and Japanese Subjects: Results from Phase I Clinical Studies.
Joseph, David; Thoma, Christian; Haeufel, Thomas; Li, Xiujiang.
Affiliation
  • Joseph D; Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Rd, Ridgefield, CT, 06877, USA.
  • Thoma C; Boehringer Ingelheim International GmbH, Biberach, Germany.
  • Haeufel T; Boehringer Ingelheim International GmbH, Ingelheim, Germany.
  • Li X; Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Rd, Ridgefield, CT, 06877, USA. xiujiang.li@boehringer-ingelheim.com.
Clin Pharmacokinet ; 61(12): 1771-1787, 2022 Dec.
Article in En | MEDLINE | ID: mdl-36451029
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Dose-Response Relationship, Drug Type of study: Clinical_trials Limits: Humans Language: En Journal: Clin Pharmacokinet Year: 2022 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Dose-Response Relationship, Drug Type of study: Clinical_trials Limits: Humans Language: En Journal: Clin Pharmacokinet Year: 2022 Document type: Article Affiliation country: Country of publication: